NKGen Biotech, Inc.

NKGen Biotech, Inc. (Nasdaq: NKGN) is a clinical-stage biopharmaceutical company focused on developing natural killer cell-based therapies targeting oncology and neurodegenerative diseases. The company entered the public markets through a business combination with Graf Acquisition Corp. IV, a blank-check vehicle sponsored by Graf Acquisition LLC, which completed its IPO in 2021. The 10-Q filing dated May 16, 2022, reflects the company's early post-merger reporting period as a combined public entity. NKGen's lead program centers on SNK01, an autologous NK cell therapy candidate advancing through clinical evaluation. For complete filing history, deal terms, and sponsor data on NKGN, sign up for full access at SpacDesk.